MolWard

The stress-testing study phase is often where the most well-intentioned timelines die. We have all experienced the frustration of developing a great HPLC method for an API, only to have a three-month stability pull reveal a co-eluting degradant that renders our previous HPLC method development obsolete. With the current regulations, a reactive approach to stability is no longer just a laboratory deviation, it is a significant business risk. Transitioning to a predictive-first analytical...

The regulatory focus on mutagenic structures has moved beyond a simple check-box exercise. With the 2024 updates to FDA and EMA nitrosamine guidance, the industry is navigating a landscape where the standard Threshold of Toxicological Concern (TTC) no longer provides a safe harbor for all impurities. Specifically, compounds within the Cohort of Concern are recognized for such high carcinogenic potency that they are theoretically associated with significant risk even at intakes below the...

The story of Ranitidine (Zantac) remains one of the most sobering cautionary tales in modern pharmaceutics. Historically, Ranitidine products passed initial release testing and met all established safety criteria. However, as the industry learned in 2019, the molecule possessed a hidden liability: it degraded over time on the shelf to form N-Nitrosodimethylamine (NDMA), a potent mutagenic carcinogen. This discovery led to massive global recalls and the eventually requested withdrawal of all...